http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004089917-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1be866e8a78ff4f87cf81deceb09546e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_09ae0c650768622238d5d135715bb48a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0b0255918a7a5fc3ed23699ec0039912
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-07
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D251-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D251-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-06
filingDate 2004-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61eabdc9011b3d279a8e733e64fee5bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e107cb397a62cd4ad3bc2e0315ed1580
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_546fafb99da7aca4b6885dcd532403c8
publicationDate 2004-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2004089917-A3
titleOfInvention Process for resolving 2,4-diamino-3,6-dihydro-1,3,5-triazines, useful for the treatment of disorders associated with insulin resistance syndrome
abstract The present invention is directed towards a process for resolving a racemic amino compound derived from dihydro- 1,3,5- triazines. The invention is also directed towards the enantiomers of amino derivatives of dihydro-1,3,5-triazines and to their use for the preparation of medicaments, in particular for the treatment of diabetes and malaria.
priorityDate 2003-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0155122-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S5414986-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3894027-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419763511
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19089942

Total number of triples: 34.